Back to Journals » OncoTargets and Therapy » Volume 12

Clinical treatment of advanced synchronous triple primary malignancies: comprehensive treatment based on targeted therapy

Authors Zhang Y, Ge Y, Wu X, Liu S

Received 7 January 2019

Accepted for publication 6 March 2019

Published 2 April 2019 Volume 2019:12 Pages 2421—2430

DOI https://doi.org/10.2147/OTT.S200625

Checked for plagiarism Yes

Review by Single-blind

Peer reviewer comments 2

Editor who approved publication: Dr William Cho


Ying Zhang, Yunjie Ge, Xiaohui Wu, Shuangmei Liu

Department of Internal Medicine, Municipal Hospital, Qingdao, Shandong, People’s Republic of China

Abstract: The prevalence of cancer remains high. With the improvement of diagnosis and treatment level and the increase of cancer survivors after treatment, multiple primary tumors are more common than before. The diagnosis and treatment of synchronous multiple primary tumors is more complicated than that of single or metachronous multiple tumors, and patients also suffer more. Because of the different conditions of these patients, lack of large-scale clinical observation data, it is necessary for clinicians to make realistic decisions on the specific conditions of patients. It is a challenge for clinicians to apply the advances of modern medicine to the diagnosis and treatment of such patients so as to prolong their survival time and improve their quality of life. This report describes the survival of an advanced elderly patient with lung, prostate and bladder cancer after receiving targeted therapy-based comprehensive treatment.

Keywords: advanced synchronous triple primary malignancies

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]